Around the world, on July 27, it was reported more than
165
vaccines against the coronavirus
Approved: 1
In Phase III: 5
Difference between Preclinical, Phase I, Phase II, Phase III, and Approval
Preclinical | Phase I | Phase II | Phase III | Approval |
Assay in animals as mice or monkeys | Small number of people | Hundreds of people, different ages. Needs to protect at least 50% of vaccinated people | Thousands of people, compared with people who received placebo. | Regulators in each country decide whether to approve the vaccine or not |
140+ | 19 | 12 | 5 | 1 |
Phase III:
Institution | Sponsor | Candidate | Phase III conducted in |
Murdoch Children’s Research Institute | University of Melbourne | Bacillus Calmette Guerin (BCG) | Australia, Spain, and Netherlands |
Sinovac Biotech | Sinovac Research and Development Co. Ltd | Coronavac | Brazil |
Wuhan Institute of Biological Products | Ministry of Science and Technology | Inactivated vaccine | United Arab Emirates |
The University of Oxford | AstraZeneca, IQVIA | AZD1222 | England, Brazil, South Africa |
National Institutes of Health | Moderna | mRna-1273 | Will start by Operation Warp Speed |
Approved: CanSino BIO
The Chinese CanSino Biologics developed this vaccine based on the adenovirus type 5 vector (Ad5). Adverse reactions as pain (54%), fever (46%), fatigue (44%) headache (39%), and muscle pain (17%) occurred in 83% of patients in the low and medium dose groups and 75% of patients in the high dose group. On 25 June, China’s Central Military commission announced the military had been approved to use Ad5-nCoV for a period of 1 year.
You must log in to post a comment.